Beijing Enruini Biotechnology

Beijing Enruini Biotechnology is a clinical-stage biopharmaceutical company focused on the development of innovative immunotherapies for the treatment of cancer and autoimmune diseases. The company specializes in engineering next-generation cytokines and antibody-based therapeutics designed to enhance the body's immune response against tumors while maintaining a favorable safety profile. Its lead program, EN-001, is a long-acting IL-15/IL-15Rα fusion protein currently undergoing clinical evaluation for advanced solid tumors. Enruini leverages its proprietary technology to address unmet medical needs through the precision modulation of immune pathways.